BioSpace News Archive

Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX® (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by Johnson & Johnson were USD 7,977 million in 2022.

NanoMosaic announced the establishment of Scientific Advisory Board (SAB) to support NanoMosaic’s vision to bring the nanoneedle-powered digital proteomic tool to the life science research and the diagnostic community.

Gritstone bio, Inc. today announced that the company’s Board of Directors granted two employees nonqualified stock options to purchase an aggregate of 28,000 shares of its common stock with an exercise price of $3.67, which is equal to the closing price of Gritstone’s common stock on January 9, 2023, the date of the grant.

Florida Urology Center today announced that John K. Burgers, MD, has joined the practice, bringing three decades of leadership and innovation in advanced robotic surgery and general urologic care to the region.

Tonix Pharmaceuticals Holding Corp. today announced the publication of a paper entitled, “ Development of a rapid image-based high-content imaging screening assay to evaluate therapeutic antibodies against the monkeypox virus,” in the journal Antiviral Research.

Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022.

First Wave BioPharma, Inc. announced James Sapirstein, Chairman, President and CEO, will present at the Sequire Biotechnology Conference being held virtually on February 2, 2023.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today provided a positive regulatory update for D-PLEX100 for the prevention of abdominal colorectal surgical site infections (SSIs).

Metagenics, Inc. (“Metagenics” or the “Company”), a leading global nutritional supplement company, today announced that it named Gavin J. Lindberg as Chief Financial Officer, effective January 17.

CollPlant is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders.